|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69.10 BRL | +4.19% |
|
+4.90% | +4.76% |
| 07-02 | Amgen Wins Preliminary Injunction to Block Colorado From Imposing Price Cap on Arthritis Drug | MT |
| 07-02 | Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial | DJ |
| Market Cap | 202B 1,050B 176B 162B 151B 286B 19,224B 291B 1,951B 756B 9,429B 758B 742B 32,490B | P/E 2026 * |
24.4x | P/E 2027 * | 22.5x |
|---|---|---|---|---|---|
| Enterprise Value | 244B 1,267B 213B 195B 182B 346B 23,194B 351B 2,354B 912B 11,377B 915B 895B 39,200B | EV / Sales 2026 * |
6.45x | EV / Sales 2027 * | 6.15x |
| Free-Float |
99.78% | Yield 2026 * |
2.7% | Yield 2027 * | 2.85% |
Last Transcript: Amgen Inc.
| 1 day | +4.19% | ||
| 1 week | +4.90% | ||
| Current month | +4.19% | ||
| 1 month | +18.12% | ||
| 3 months | +7.90% | ||
| 6 months | +42.77% | ||
| Current year | +4.76% |
| 1 week | 65.66 |  | 69.1 |
| 1 month | 62.29 | | 69.1 |
| Current year | 48.4 | | 78.13 |
| 1 year | 48.4 | | 78.13 |
| 3 years | 38 | | 78.13 |
| 5 years | 37.52 | | 78.13 |
| 10 years | 15.78 | | 78.13 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 63 | 2012-04-30 |
| Director of Finance/CFO | 62 | 2010-05-12 | |
Peter Griffith
DFI | Director of Finance/CFO | 67 | 2019-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 63 | 2012-12-31 |
Tyler Jacks
BRD | Director/Board Member | 65 | 2011-12-31 |
Robert Eckert
BRD | Director/Board Member | 71 | 2011-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.19% | +4.90% | - | - | 202B | |
| +1.86% | +7.65% | +55.77% | +158.84% | 1,082B | |
| +3.57% | +7.42% | +69.09% | +58.92% | 633B | |
| +3.99% | +7.37% | +36.87% | +93.77% | 461B | |
| +2.77% | -1.94% | +26.41% | +20.22% | 339B | |
| -1.22% | +0.46% | +40.96% | +38.65% | 301B | |
| -0.47% | +0.98% | +31.74% | +44.03% | 292B | |
| -1.99% | +2.47% | -25.60% | -39.81% | 225B | |
| +4.21% | +6.00% | +17.72% | +70.33% | 163B | |
| +1.84% | +2.75% | -3.95% | -33.70% | 139B | |
| Average | +1.40% | +3.77% | +27.67% | +45.69% | 404.04B | |
| Weighted average by Cap. | +1.27% | +4.94% | +40.78% | +77.47% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 37.76B 196B 33B 30.3B 28.26B 53.57B 3,595B 54.47B 365B 141B 1,763B 142B 139B 6,076B | 38.71B 201B 33.83B 31.06B 28.97B 54.92B 3,686B 55.84B 374B 145B 1,808B 145B 142B 6,229B |
| Net income | 8.23B 42.81B 7.19B 6.6B 6.16B 11.68B 784B 11.87B 79.52B 30.82B 384B 30.91B 30.24B 1,324B | 8.86B 46.11B 7.75B 7.11B 6.63B 12.58B 844B 12.79B 85.64B 33.19B 414B 33.29B 32.56B 1,426B |
| Net Debt | 41.7B 217B 36.44B 33.46B 31.21B 59.16B 3,970B 60.16B 403B 156B 1,947B 157B 153B 6,710B | 36.06B 188B 31.51B 28.93B 26.98B 51.15B 3,433B 52.01B 348B 135B 1,684B 135B 132B 5,802B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-02 | R$69.10 | +4.19% | 1,015 |
| 26-06-29 | R$66.32 | +0.15% | 1,728 |
| 26-06-26 | R$66.22 | +0.53% | 522 |
| 26-06-25 | R$65.87 | +0.81% | 1,531 |
| 26-06-24 | R$65.34 | +1.59% | 1,306 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AMGN Stock
- AMGN34 Stock
Select your edition
All financial news and data tailored to specific country editions
